FDA Publishes 2026–2027 EL-PFDD Meeting Schedule Covering 13 Rare Disease Areas

Thirteen rare and complex disease areas now have confirmed or anticipated Externally-Led Patient-Focused Drug Development (EL-PFDD) meeting dates stretching from June 2026 through February 2027, a pipeline that regulatory affairs teams should treat as an early-stage indicator of future NDA/BLA activity and the manufacturing scale-up demands that follow.

FDA's Center for Drug Evaluation and Research (CDER) published the updated schedule on its EL-PFDD webpage, listing each disease area alongside the patient advocacy organization that submitted a letter of intent (LOI) and serves as the primary point of contact. The agency does not conduct these meetings and the listing carries no endorsement, but the schedule reflects where structured patient-experience data collection is advancing under the Prescription Drug User Fee Amendments (PDUFA) framework.

The confirmed dates span a broad therapeutic range. Down Syndrome-Associated Alzheimer's Disease opens the cycle on June 2, 2026, followed by Maternal Alloimmunization and Hemolytic Disease of the Fetus and Newborn on July 20. The autumn cluster is dense: Lipodystrophy (September 11), Spinal Cord Injury (September 29), Fanconi Anemia (October 3), SCN2A (October 23), APOL1 Kidney Disease and Giant Axonal Neuropathy (both November 6), Pitt Hopkins Syndrome (November 13), POLG-related mitochondrial disorders (November 17), Mucormycosis (November 19), and Sickle Cell Disease (December 1). Primary CoQ10 Deficiency closes the published window on February 16, 2027.

For regulatory affairs leads, the relevance is sharpest around submission planning. EL-PFDD outputs feed directly into FDA's benefit-risk assessments and, in rare disease contexts, can accelerate the patient-experience data sections of a dossier. Organizations tracking any of these indications should engage with the relevant advocacy group now to understand data-collection methodology before meeting outputs are finalized.

Plant heads and CMC teams have a parallel read: several conditions on the list, including Fanconi Anemia, Giant Axonal Neuropathy, and POLG-related mitochondrial disorders, are associated with small patient populations where clinical-to-commercial manufacturing transitions carry heightened process validation and sterility assurance complexity. Early visibility into the development timeline allows manufacturing functions to begin capacity and comparability planning well ahead of a potential BLA filing window.

The February 2027 Primary CoQ10 Deficiency meeting marks the current end of the published schedule, though FDA notes that multiple organizations may be collaborating on individual meetings and that the list will be updated as additional LOIs are accepted.

Source: FDA CDER What's New: Drugs RSS Feed via fda.gov, May 6, 2026.